Wellington Management Group LLP purchased a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the second quarter, HoldingsChannel.com reports. The firm purchased 121,769 shares of the exchange traded fund’s stock, valued at approximately $19,270,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in XBI. Axiom Investment Management LLC bought a new position in SPDR S&P Biotech ETF during the first quarter worth about $26,000. Financial Life Planners bought a new position in SPDR S&P Biotech ETF in the first quarter valued at approximately $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of SPDR S&P Biotech ETF in the 4th quarter valued at $27,000. Intesa Sanpaolo Wealth Management acquired a new position in SPDR S&P Biotech ETF during the fourth quarter worth about $30,000. Finally, SHP Wealth Management acquired a new position in SPDR S&P Biotech ETF during the 4th quarter worth approximately $31,000.
SPDR S&P Biotech ETF Stock Performance
Shares of XBI opened at $163.81 on Monday. SPDR S&P Biotech ETF has a 52 week low of $92.64 and a 52 week high of $169.89. The stock has a fifty day moving average of $158.18 and a 200-day moving average of $140.63. The stock has a market capitalization of $10.70 billion, a price-to-earnings ratio of 11.47 and a beta of 0.84.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- AI Token Costs Are Changing the Hardware vs. Software Debate
- 3 ETFs That Could Move as Rate Expectations Shift
- 3 Stocks With September Catalysts Investors Shouldn’t Ignore
- Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
